Liver study tests drug safety in impaired patients
NCT ID NCT06052566
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This study looked at how the body processes efinopegdutide, a drug for fatty liver disease, in people with moderate to severe liver damage compared to healthy volunteers. Researchers measured drug levels in the blood and checked for side effects after a single dose. The goal was to understand if liver problems change how the drug works, helping guide future dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Pharma CR, LLC ( Site 0001)
Miami, Florida, 33147, United States
-
American Research Corporation ( Site 0002)
San Antonio, Texas, 78215, United States
-
Clinical Pharmacology of Miami ( Site 0005)
Miami, Florida, 33014-3616, United States
-
Genesis Clinical Research, LLC ( Site 0006)
Tampa, Florida, 33603, United States
Conditions
Explore the condition pages connected to this study.